Heart Disease Clinical Trials in San Francisco

Showing 81-100 of 167 trials

Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry

NCT04669548

The Accuryn Registry Study is an open-ended, global, multi-center, retrospective and prospective, single-arm data collection study with an FDA cleared device. The target population are cardiovascular surgery patients. Physiologic data measurements will be collected from enrolled subjects using electronic medical records and data streams via the Accuryn Monitoring System.

Intraabdominal HypertensionAbdominal Compartment SyndromeAcute Kidney Injury+1 more

Potrero Medical2,500 participantsStarted Dec 2020

Los Angeles, California, United States • San Francisco, California, United States • Washington D.C., District of Columbia, United States +6 more locations

COMPLETEDPHASE4< 1 mile

Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy

NCT02836652

This study is a prospective, multi-center, randomized, double-blind placebo-controlled study of subjects receiving the HM II LVAD as per the current FDA approved indications for use.

Heart Failure

Abbott Medical Devices72 participantsStarted Nov 2016

Birmingham, Alabama, United States • Los Angeles, California, United States • San Diego, California, United States +32 more locations

Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry

Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy

Heart Disease Trials in Other Cities

Thoratec HeartMate II Left Ventricular Assist System (LVAS) for Bridge to Cardiac Transplantation

Cardiac Recovery Through Dietary Support

Improving Critical Congenital Heart Disease Screening With Addition of Perfusion Measurements

Congenital Heart Initiative-Redefining Outcomes and Navigation to Adult Centered Care

Kaiser Permanente Evaluation of Medically Tailored Meals in Adults With Medical Conditions at High Readmission Risk

Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction

A Digital Flu Intervention for People With Cardiovascular Conditions

Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)

Adverse Metabolic Effects of Dietary Sugar

The Effect of Anesthesia on Neurodevelopmental Outcome (NDO)

Health Literacy in Adults With Congenital Heart Disease

Precision Event Monitoring for Patients With Heart Failure Using HeartLogic

Incidental Coronary Calcification Quality Improvement Project

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

SHIELD II Clinical Investigation

Chronic Total Occlusion Percutaneous Coronary Intervention Study

Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion

Restore EF Observational Study

Other Conditions in San Francisco